Show simple item record

dc.contributor.authorKansikas, Minttu
dc.contributor.authorVähätalo, Laura
dc.contributor.authorKantelinen, Jukka
dc.contributor.authorKasela, Mariann
dc.contributor.authorPutula, Jaana
dc.contributor.authorDøhlen, Anni
dc.contributor.authorPaloviita, Pauliina
dc.contributor.authorKärkkäinen, Emmi
dc.contributor.authorLahti, Niklas
dc.contributor.authorArnez, Philippe
dc.contributor.authorKilpinen, Sami
dc.contributor.authorAlcala-Repo, Beatriz
dc.contributor.authorPylvänäinen, Kirsi
dc.contributor.authorPöyhönen, Minna
dc.contributor.authorPeltomäki, Päivi
dc.contributor.authorJärvinen, Heikki J.
dc.contributor.authorSeppälä, Toni T.
dc.contributor.authorRenkonen-Sinisalo, Laura
dc.contributor.authorLepistö, Anna
dc.contributor.authorMecklin, Jukka-Pekka
dc.contributor.authorNyström, Minna
dc.date.accessioned2023-03-28T07:31:15Z
dc.date.available2023-03-28T07:31:15Z
dc.date.issued2023
dc.identifier.citationKansikas, M., Vähätalo, L., Kantelinen, J., Kasela, M., Putula, J., Døhlen, A., Paloviita, P., Kärkkäinen, E., Lahti, N., Arnez, P., Kilpinen, S., Alcala-Repo, B., Pylvänäinen, K., Pöyhönen, M., Peltomäki, P., Järvinen, H. J., Seppälä, T. T., Renkonen-Sinisalo, L., Lepistö, A., . . . Nyström, M. (2023). Tumor-independent Detection of Inherited Mismatch Repair Deficiency for the Diagnosis of Lynch Syndrome with High Specificity and Sensitivity. <i>Cancer Research Communications</i>, <i>3</i>(3), 361-370. <a href="https://doi.org/10.1158/2767-9764.CRC-22-0384" target="_blank">https://doi.org/10.1158/2767-9764.CRC-22-0384</a>
dc.identifier.otherCONVID_177502284
dc.identifier.urihttps://jyx.jyu.fi/handle/123456789/86140
dc.description.abstractLynch syndrome (LS) is the most common hereditary cancer syndrome. Early diagnosis improves prognosis and reduces health care costs, through existing cancer surveillance methods. The problem is finding and diagnosing the cancer predisposing genetic condition. The current workup involves a complex array of tests that combines family cancer history and clinical phenotypes with tumor characteristics and sequencing data, followed by a challenging task to interpret the found variant(s). On the basis of the knowledge that an inherited mismatch repair (MMR) deficiency is a hallmark of LS, we have developed and validated a functional MMR test, DiagMMR, that detects inherited MMR deficiency directly from healthy tissue without need of tumor and variant information. The validation included 119 skin biopsies collected from clinically pathogenic MMR variant carriers (MSH2, MSH6) and controls, and was followed by a small clinical pilot study. The repair reaction was performed on proteins extracted from primary fibroblasts and the interpretation was based on the MMR capability of the sample in relation to cutoff, which distinguishes MMR proficient (non-LS) from MMR deficient (LS) function. The results were compared with the reference standard (germline NGS). The test was shown to have exceptional specificity (100%) with high sensitivity (89%) and accuracy (97%). The ability to efficiently distinguish LS carriers from controls was further shown with a high area under the receiving operating characteristic (AUROC) value (0.97). This test offers an excellent tool for detecting inherited MMR deficiency linked to MSH2 or MSH6 and can be used alone or with conventional tests to recognize genetically predisposed individuals. Significance: Clinical validation of DiagMMR shows high accuracy in distinguishing individuals with hereditary MSH2 or MSH6 MMR deficiency (i.e., LS). The method presented overcomes challenges faced by the complexity of current methods and can be used alone or with conventional tests to improve the ability to recognize genetically predisposed individuals.en
dc.format.mimetypeapplication/pdf
dc.language.isoeng
dc.publisherAmerican Association for Cancer Research (AACR)
dc.relation.ispartofseriesCancer Research Communications
dc.rightsCC BY 4.0
dc.titleTumor-independent Detection of Inherited Mismatch Repair Deficiency for the Diagnosis of Lynch Syndrome with High Specificity and Sensitivity
dc.typearticle
dc.identifier.urnURN:NBN:fi:jyu-202303282281
dc.contributor.laitosLiikuntatieteellinen tiedekuntafi
dc.contributor.laitosFaculty of Sport and Health Sciencesen
dc.type.urihttp://purl.org/eprint/type/JournalArticle
dc.type.coarhttp://purl.org/coar/resource_type/c_2df8fbb1
dc.description.reviewstatuspeerReviewed
dc.format.pagerange361-370
dc.relation.issn2767-9764
dc.relation.numberinseries3
dc.relation.volume3
dc.type.versionpublishedVersion
dc.rights.copyright© 2023 The Authors; Published by the American Association for Cancer Research
dc.rights.accesslevelopenAccessfi
dc.subject.ysosyöpätaudit
dc.subject.ysovalidointi
dc.subject.ysoLynchin oireyhtymä
dc.subject.ysosyöpägeenit
dc.subject.ysodiagnostiikka
dc.subject.ysotestausmenetelmät
dc.format.contentfulltext
jyx.subject.urihttp://www.yso.fi/onto/yso/p678
jyx.subject.urihttp://www.yso.fi/onto/yso/p20652
jyx.subject.urihttp://www.yso.fi/onto/yso/p23697
jyx.subject.urihttp://www.yso.fi/onto/yso/p23580
jyx.subject.urihttp://www.yso.fi/onto/yso/p416
jyx.subject.urihttp://www.yso.fi/onto/yso/p26360
dc.rights.urlhttps://creativecommons.org/licenses/by/4.0/
dc.relation.doi10.1158/2767-9764.CRC-22-0384
jyx.fundinginformationThis work has been supported by research grants from the Jane and Aatos Erkko Foundation (P. Peltomäki, M. Nyström, J.-P. Mecklin, T.T. Seppälä); the Academy of Finland (grant number 330606, to P. Peltomäki); Cancer Foundation Finland sr (P. Peltomäki, T.T. Seppälä, J.-P. Mecklin); the Sigrid Juselius Foundation (P. Peltomäki, T.T. Seppälä); the HiLIFE Fellows 2017–2020 (to P. Peltomäki), the Emil Aaltonen Foundation (T.T. Seppälä), the Relander foundation (T.T. Seppälä), State Research Funding (J.-P. Mecklin), and LS CancerDiag Ltd and Business Finland (grant number 1438_31_2015).
dc.type.okmA1


Files in this item

Thumbnail

This item appears in the following Collection(s)

Show simple item record

CC BY 4.0
Except where otherwise noted, this item's license is described as CC BY 4.0